Trial Profile
A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Ibrutinib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 03 Jun 2019 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 10 Oct 2016 Status changed from recruiting to active, no longer recruiting.